Walk down the yogurt aisle and something is different. The section has doubled in length. High-protein labels are everywhere. Cottage cheese has its own endcap. The snack aisle, meanwhile, has sprouted smaller bags, single-serve packs, and more “high-fiber” claims than anyone can remember seeing two years ago.
Something has shifted on the American grocery shelf, and most people haven’t been told why. The short answer: a class of drugs that started as a diabetes treatment has quietly become one of the most disruptive forces the food industry has faced in decades. The reformulation race is already underway, and it’s only in its early innings.
What GLP-1s Actually Do
GLP-1 receptor agonists (sold under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound) work by slowing gastric emptying, dulling cravings, and reducing overall appetite. Users typically consume meaningfully fewer calories per day, not because they’re choosing to, but because they’re genuinely less hungry.
GLP-1 use by American adults has more than doubled in roughly a year and a half. By 2030, more than 30 million Americans could be on a GLP-1 treatment, up from around 10 million in 2026, based on analyst estimates. Oral versions are now entering the market, which is expected to widen access further, moving GLP-1s from a niche medical category to something closer to a mass-market behavioral shift.
The food industry noticed.
The Categories That Are Quietly Losing
GLP-1 users aren’t deciding chips are bad. They’re simply less hungry. That distinction matters, because the behavioral shift is physiological rather than ideological, and it’s hitting specific categories hard.
Snacking has taken the biggest impact, because the entire “eat something between meals” occasion is what these drugs most directly suppress. About 70% of GLP-1 users who report consuming fewer calories say they are snacking less. Savory snacks, sweet bakery, candy, soft drinks, and indulgent frozen meals, the categories built around grazing and impulse eating, are all feeling the pressure.
Dinner traffic at fast food restaurants has fallen meaningfully among regular GLP-1 users. The broader snack industry is recalibrating. Clean label claims, portion control, and functional benefits like protein, fiber, and gut health are increasingly driving purchase decisions. The days of snacks as pure indulgence may not be over, but they are being reimagined.
The Reformulation Race
This is where the story gets genuinely interesting. Food companies have realized this isn’t a fad, and the response across the industry has been fast.
Several levers are being pulled simultaneously. Sugar reduction is one: stevia, monk fruit, allulose, and fiber-based sweetness systems are replacing traditional sugar across dairy, beverages, and baked goods. The goal is products that still taste satisfying but don’t deliver the calorie load GLP-1 users no longer want.
Protein is the bigger story. Whey, casein, pea, soy, and dairy protein concentrates are appearing in categories that historically had none of them: cereals, crackers, snack bars, even frozen meals. GLP-1 users prioritize protein per bite and favor high fiber, while seeking smaller serving sizes and new beverage formats. Brands are responding directly to that preference profile.
Fiber additions are following the same trajectory: chicory root, inulin, and oat fiber are being built into products for satiety and digestive support. Functional ingredients like prebiotics for gut health and electrolytes for hydration are appearing in categories where they had no precedent.
Nestlé launched its Vital Pursuit line with “GLP-1 Support” badges across bowls, fajitas, and pizzas. Abbott introduced Protality nutrition shakes specifically designed for GLP-1 users. Conagra rolled out its “On Track” badge on products across its Healthy Choice and Simply portfolios, highlighting protein, fiber, and GLP-1 compatibility.
The same companies that spent decades engineering products optimized for maximum palatability are now running the process in reverse. That’s a significant operational shift, and it involves the entire supply chain, not just the marketing department.
The Yogurt Boom and the Surprising Winners
One category deserves its own section because the story is so vivid.
The yogurt aisle in 2026 looks nothing like the yogurt aisle in 2019. High protein, gut friendly, easy to fortify, naturally portion controlled: yogurt checks nearly every box GLP-1 users are looking for. Positioning yogurt, cottage cheese, and dairy beverages as GLP-1 friendly is unlocking significant growth opportunities, with brands adding new layers of functionality including creatine, probiotics, and additional protein fortification.
Cottage cheese is perhaps the most visible symbol of the shift. A category that had been slowly declining for years has experienced a full renaissance, driven partly by social media and partly by the fact that it happens to be dense in protein, low in sugar, and easy to eat in small portions. Yogurt, protein shakes, and frozen dairy offer an ideal balance for GLP-1 users: smaller portions that still feel indulgent, textures that satisfy, and nutrient density that supports metabolic wellness in a convenient format.
Other winners include snack bars reformulated with higher protein, ready to drink protein beverages, fortified kefirs, and some confectionery brands that have successfully repositioned toward smaller, more functional formats.
The “GLP-1 Friendly” Label Problem
Some brands have started placing “GLP-1 friendly” badges directly on packaging. The debate inside the industry is real.
On one side: the badge is useful shorthand for the roughly 31 million Americans now on these medications who are actively looking for products suited to how they’re eating. On the other: tying a brand’s positioning to a specific drug class is a long-term bet that carries risk, and the term is entirely unregulated. Claim words are all over the map: “GLP-1 Activator,” “Booster,” “Friendly,” “Nutrition,” “Support,” and all are unregulated by the FDA.
Most analysts believe the strongest long-term play is quiet reformulation across the portfolio rather than loud badging on a single SKU. A product that’s higher in protein and fiber and lower in sugar serves GLP-1 users, and it also serves the much larger population of consumers who simply want to eat better. The badge may be narrowing.
What This Means Upstream
Behind every reformulated yogurt, every protein-fortified cracker, and every fiber-boosted bar is a supply chain that had to change too. Protein concentrates, prebiotic fibers, natural sweeteners, and functional ingredients are now in meaningfully higher demand, and the suppliers who can deliver them at scale, with consistent quality and clean documentation, are the quiet beneficiaries of the GLP-1 wave.
The upstream pressure is real: sourcing the right inputs, at the right spec, with the certifications consumers and retailers expect, is not a simple logistics problem. It’s an ingredient strategy problem. And as CPG brands race to reformulate their portfolios, they’re also confronting one of the oldest lessons in the industry. The long history of CPG brands learning that lesson the hard way is worth understanding before you start changing things customers already love.
The Bigger Picture
The food industry has reformulated before. Low fat in the 1980s. Low carb in the 2000s. Plant based in the 2010s. Each wave reshaped categories, created winners, and left others behind.
The GLP-1 wave is structurally different. Previous cycles were driven by consumer choice, people deciding they wanted to eat differently. This one is driven by physiology. People aren’t choosing to eat less; they are less hungry. That makes the behavioral change more durable than any diet trend that preceded it.
GLP-1 users are forecast to represent a meaningful share of US food and beverage spend by 2030. The companies that started reformulating in 2024 and 2025 are already ahead. The ones still treating this as a niche concern are running out of time to catch up.
The grocery shelf will keep changing. Now you know why.
Why it matters
Every reformulation wave creates new sourcing requirements upstream. The protein concentrates, prebiotic fibers, natural sweeteners, and functional ingredients driving GLP-1 product innovation all need suppliers who can deliver them consistently, at scale, and with the documentation retailers and brands require. That’s the supply chain story behind what’s happening on the shelf.
For CPG brands navigating ingredient sourcing for reformulation, the Source86 team works with procurement and R&D teams to identify the right suppliers for exactly these inputs. Reach out to start the conversation.
